Kornimate/medical-research-clean huggingface dataset:
risk factors of recovery room delirium after elective non-cardiovascular surgery

Conditions: Delirium

Summary: despite recent advances in postoperative delirium research, the proportion of patients with postoperative delirium is still high ranging between 20-80%. although postoperative delirium is a frequent complication and is associated with the need for more inpatient hospital care and longer length of hospital stay, little is known about risk factors for recovery room delirium (rrd) occurred in postanaesthesia care unit. the aim of the study was to determine pre- and intraoperative risk factors for the development of rrd among patients undergoing non cardiovascular surgery.

recovery room delirium (rrd) defined as delirium occurred in pacu was diagnosed according to cam-icu criteria. pre-, intra-, and postoperative data of patients undergoing elective non cardiovascular surgery were prospectively collected, univariate and multivariate logistic regression were performed to find the risk factors related to postoperative delirium.

Eligibility criteria:
inclusion criteria: * elective non-cardiovascular surgery * general anesthesia exclusion criteria: * under 18yr of age * under regional anaesthesia * refused to sign consent form * history of substance dependence * underwent neurosurgery * history of primary neurologic diseases * stayed less than 10min in pacu * received general anaesthesia but recovered in locations outside the recovery room

Keywords: delirium postoperative non-cardiovascular surgery post-anaesthesia care unit
autonomic dysfunction in patients following bariatric surgery: the adipose study

Conditions: Autonomic Dysfunction; Orthostatic Intolerance

Summary: observational two phase, retrospective and prospective registry study to assess the prevalence of and characterize outcomes of autonomic dysfunction (ad) in patients who undergo bariatric surgery (bs) and to better define the underlying pathophysiology of ad following bs.

previous studies have investigated the incidence of oi (orthostatic intolerance) with bs. one recent meta-analysis only found a 5-year cumulative incidence of 4.2%, challenging reports of increased incidence. however, this same study recognized the limited and low-quality evidence investigating this phenomenon. other meta-analyses found only four studies each that matched their search criteria, highlighting the lack of evidence. thus, this study is designed to investigate the prevalence and better understand ad/oi after bs.

Eligibility criteria:
inclusion criteria: * between the age of 18 - 85 years * can provide consent * negative urine b-hcg * continued follow-up with the bariatric surgery team. * bs includes one of the following: gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch. * phase i: underwent bs within the last 3 years * phase ii: will undergo bs within the next 3 months or underwent bs in the last 30 days exclusion criteria: * unable to provide consent * pregnant or breastfeeding * bmi \< 35 * revision surgery of one of the following bs from above * prior history of autonomic dysfunction prior to bs * developed ad 72 months post-procedure * no evidence of ad/oi
soy supplements in treating patients undergoing surgery for localized prostate cancer

Conditions: Prostate Cancer

Summary: rationale: dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. purpose: this randomized phase ii trial is studying a soy supplement to see how well it works compared to a placebo in treating patients undergoing surgery for localized prostate cancer.

objectives: primary * compare the effect of dietary supplementation with soy vs placebo on biomarkers of cell cycle regulation, proliferation, differentiation, apoptosis, and signaling pathways in patients with localized prostate cancer scheduled to undergo radical prostatectomy. secondary * compare the toxicity and side effects of these regimens in these patients. * compare the dietary patterns of these patients. outline: this is a prospective, randomized study. patients are randomized to 1 of 2 treatment arms. * arm i: patients receive oral soy supplementation daily for 4 weeks. * arm ii: patients receive oral placebo supplementation daily for 4 weeks. patients undergo radical prostatectomy within 21 days after completion of soy or placebo supplementation. blood and tissue samples are collected for biomarker analysis using immunohistochemistry.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the prostate * clinically localized disease * scheduled for radical prostatectomy * no evidence of metastatic disease by bone scan or ct scan of the abdomen or pelvis patient characteristics: * ecog performance status 0-2 * no evidence of active nephrolithiasis * no history of hypercalcemic syndrome prior concurrent therapy: * no prior treatment for prostate cancer, including radiotherapy, systemic chemotherapy, surgery, or investigational drugs * no other concurrent dietary supplementation with soy, cholecalciferol (vitamin d), or fish oil

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
the effects of perioperative dexmedetomidine administration on immune suppression and outcomes in patients with uterine cancer undergoing radical resection

Conditions: Uterine Cancer

Summary: surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. the natural killer (nk) cell is a critical part of anti-tumor immunity. dexmedetomidine has sympatholytic effect and preserves nk cell function. this study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.


Eligibility criteria:
inclusion criteria: * patient between 20 and 70 of age with asa physical status ⅰ-ⅲ * patient scheduled for uterine cancer surgery exclusion criteria: * asa physical status ⅳ * severe hepatorenal disease * infection * metastasis to other organ * problem with communication
brief pain reprocessing therapy in veterans

Conditions: Chronic Lower Back Pain (CLBP)

Summary: this research is studying whether a zoom-based behavioral intervention may have an impact as a treatment for veterans with chronic low back pain (clbp). the study will examine: * the acceptability of the brief pain reprocessing therapy (bprt) intervention * the feasibility of the bprt intervention * the safety of the bprt intervention

this study will take place remotely and there will be no on-site visits.

Eligibility criteria:
inclusion criteria: * low back pain that has lasted greater than 6 months, with pain on at least half of these days * must provide verification of being an armed service veteran. * able to read, write and speak english * internet access and audio-conferencing capability (e.g., zoom meetings by phone or computer) in the home exclusion criteria: * self-reported evidence of a separate medical condition (e.g., rheumatoid arthritis), acute injury in the past 12 months (e.g., self-reported spinal fracture), self-reported loss of bowel or bladder control in the past year (which may indicate presence of cauda equina syndrome), or evidence of presence of a metastasizing cancer requiring treatment * pending surgical procedures or interventional therapies (e.g., spinal injections) within the next 12 months * confirmed/suspected pregnancy * evidence of other conditions that may preclude participants from understanding or being able to participate in study procedure (e.g., schizoaffective disorder, suspected or diagnosed dementia) * currently receiving cognitive-behavioral therapy or other psychological therapies for pain * open litigation in the past 1 year, as assessed in preliminary study screening. * any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.

Keywords: veterans telehealth based intervention brief pain reprocessing therapy
to develop and introduce into polyclinic practice a register of patients with experience of myocardial infarction and acute cerebrovascular disease

Conditions: Myocardial Infarction (MI); Acute Cardiovascular Disease

Summary: this is a retrospective observational study using the methodology of creating medical registries. the expected number of patients included in the registry is about 2000 patients with myocardial infarction and/or acvd of any duration and concomitant non-cardiac diseases of therapeutic profile in pilot healthcare organizations for any reason during 2019-2022 based on the source medical records data.

the implementation of the task results will improve the efficiency of secondary and tertiary prevention of diseases of the circulatory system - pathology that makes the greatest contribution to the main medical-demographic and socio-economic losses of the state by determining the number of groups with the highest risk of death in outpatient and polyclinic institutions among patients after myocardial infarction, acvd, living in the republic of belarus, to create programs of additional measures to reduce morbidity and mortality of the population based on a comparison of register data and official statistical forms, which will ultimately affect the reduction in the incidence of non-fatal recurrent cardiovascular events in individuals after ami, acvd and / or their combination of any duration in the range of 0.2-1% of the indicators determined during the study.

Eligibility criteria:
inclusion criteria: 1. all patients who applied to the pilot ambulatory health care organizations between 2019-2022 in order to identify and "look for" patients after acute cardiovascular event, but who were not monitored for that event for various reasons (statute of limitations, refusal, relocation, etc.); 2. all patients discharged from hospitals with a final diagnosis of ami/acvd, assigned territorially to the pilot polyclinics in the period 2019-2022. 3. presence of a history of ami and/or acvd; 4. age 18 years and older. exclusion criteria: * no

Keywords: registry multimorbidity chronic non-communicable diseases cardiovascular diseases myocardial infarction acute cerebrovascular disease
colour vision impairment during acute hypobaric hypoxia

Conditions: Hypoxia, Altitude

Summary: this study analyses the impairment of colour vision during hypobaric hypoxia in volunteers of different groups.

this study analyses the impairment of colour vision during hypobaric hypoxia in volunteers of different groups. five different groups were analysed: * ground control binocular (n=12, bi/gc) * ground control monocular (n=11, mo/gc) * 10,000 ft, 60 min, monocular (n=10, mo/60/10,000) * 15,000 ft, 15 min, binocular (n=11, bi/15/15,000) * 15,000 ft, 60 min, monocular (n=10, mo/60/15,000)

Eligibility criteria:
inclusion criteria: * volunteers from 18 years old exclusion criteria: * cardiovascular, pulmonary, neurological, or ear, nose, and throat disease * pregnant or suffering from cold symptoms
safety on switching between different botulinum toxin-a

Conditions: Cerebral Palsy

Summary: clinical guidelines recommend the use of botulinum toxin-a (bont-a) for localized/segmental spasticity in children with cerebral palsy. at the kocaeli university (kou) department of physical medicine and rehabilitation (pmr) more than 800 patients have been injected with the two approved toxina types; onabotulinumtoxina or abobotulinumtoxina. with this study investigators would like to evaluate retrospectively if switching from one toxin to another is safe as well as to evaluate if the efficacy when switching from one toxin to another was maintained.

a data base was designed to capture all data that were considered relevant to the treatment evaluation. the data were transcribed directly from participants medical records. for the purpose of the study, data from the two subsequent visits where a different type of toxin was given will be collected and evaluated . in order to collect the pre and post status in terms of safety and efficacy, for each participant, data corresponding to the 6 previous and posterior months after the switch of the toxin will also be collected or data corresponding to the previous and posterior visit after the switch of the toxin will also be collected.

Eligibility criteria:
inclusion criteria: * children diagnosis of cerebral palsy with respect to rosenbaum criteria, * children having received repeated injections with two different types of toxina treatment into their lower limb(s) exclusion criteria: * children without repeated botulinum toxin type a injections * children having received repeated injections with same type of toxina

Keywords: botulinum toxin-a
the north kynouria project

Conditions: Cardiovascular Diseases; Heart Diseases; Cerebrovascular Disease; Coronary Disease; Dyslipidemias; Stroke (CVA) or TIA; Myocardial Infarction; Hypertension; Diabetes Mellitus; Peripheral Artery Disease

Summary: the north kynouria project was initiated to study cardiovascular/stroke risk factors by employing mass screening and long-term surveillance of an adult population in the municipality of north kynouria, in the county of arcadia, peloponnese, greece. the north kynouria study was initiated to assess modifiable and non-modifiable determinants of cerebrovascular and coronary heart disease.

background: the north kynouria project is a longitudinal, interventional-behavioural, prospective study aiming to identify cardiovascular/stroke risk factors, in the adult population of the municipality of north kynouria, in the county of arcadia, peloponnese, greece. the project, initiated in november 2022, recruits volunteers, of both sexes, over 18 years of age, irrespective of their personal history of cardiovascular disease. the epidemiology and burden of cardiovascular disease in north kynouria remain unknown. the study aims to explore and document the prevalence of major cardiovascular/stroke risk factors, as well as the nutritional status, cigarette smoking, exercise habits, alcohol consumption, and overall quality of life of the inhabitants. design narrative: the screening exam is conducted at the astros, health center, by obtaining the patient's personal history, and information about the patient's habits, such as physical activity, smoking, and alcohol consumption. body weight, height, and waist-to-hip ratio are also measured. during the examination, blood pressure is evaluated using a pre-specified protocol, including assessment of orthostatic hypertension. further testing includes electrocardiography, ankle-brachial index, direct ophthalmoscopy, and carotid and cardiac ultrasound. blood samples are collected and stored at the deep freeze of the astros premises, and blood count, lipid panel, and liver and kidney function are measured. the main field of interest is the prevalence and burden of risk factors and cardiovascular disease in the wider region of north kynouria, arcadia greece. the project aims to assess the epidemiology of cvd and consequently improve public health and engage with the local community through healthy behavioral education.

Eligibility criteria:
inclusion criteria: * residents of north kynouria exclusion criteria: * under 18, * pregnancy

Keywords: atherosclerosis vascular disease arterial occlusive diseases
study evaluating osseospeed™ narrow implant in the upper and lower anterior jaw

Conditions: Jaw, Edentulous, Partially

Summary: to evaluate 5-year survival, functionality and safety for osseospeed™ 3.0 mm diameter implant when used for single tooth crown in positions 12, 22, 31, 32, 41 and 42. the primary hypothesis is that implant survival after 5 years is equal to what has been observed with comparable implants in current literature.


Eligibility criteria:
inclusion criteria: * provision of informed consent * aged 18-70 years at enrolment * history of edentulism in the study area of at least two months * presence of natural tooth roots adjacent to the study implant position * deemed by the investigator to have a bone height and width suitable for 3.0 mm diameter study implant * deemed by the investigator as likely to present an initially stable implant situation exclusion criteria: * unlikely to be able to comply with study procedures, as judged by the investigator * uncontrolled pathologic processes in the oral cavity * known or suspected current malignancy * history of radiation therapy in the head and neck region * history of chemotherapy within 5 years prior to surgery * systemic or local disease or condition that could compromise post-operative healing and/or osseointegration, as deemed by the investigator * uncontrolled diabetes mellitus * corticosteroids or any other medication that could influence post-operative healing and/or osseointegration * smoking more than 10 cigarettes per day * present alcohol and/or drug abuse * involvement in the planning and conduct of the study (applies to both astra tech staff and staff at the study site) * previous enrolment in the present study * simultaneous participation in another clinical study, or participation in a clinical study during the last weeks prior to enrolment
postoperative analgesia in bilateral knee arthroplasties

Conditions: Knee Arthroplasty, Total; Peripheral Nerve Block; Pain, Postoperative

Summary: to observationally compare the analgesic efficacy of lia and s-ficb techniques and to record the pain scores of patients who underwent bilateral knee operations in the postoperative period.


Eligibility criteria:
inclusion criteria: * planned elective bilateral knee arthroplasty under spinal anesthesia * american society of anesthesiologists (asa) risk score i-ii * patients aged 18-75 years exclusion criteria: * those receiving general anesthesia, * those with epidural catheters, * those who refused to participate in the study, * those whose spinal anesthesia failed and returned to general anesthesia, * those with a body mass index (bmi) \>30 kg/m2, * history of chronic opioid or corticosteroid use, * patients with psychiatric or neurological problems that would not allow assessment of pain using a visual analog scale (vas) will be excluded. * in addition, patients whose surgery lasted \ 120 minutes will also be excluded to keep the data homogeneous.

Keywords: pain pain management nerve block
functional eletrical stimulation in post stroke patients

Conditions: Stroke

Summary: the fes-able project results from an iberian partnership and aims to evaluate the impact of an intervention based on a functional electrical stimulation (fes) prototype on the upper limb movement quality during functional tasks. the results of this project will contribute to the definition of the therapeutic window of fes to improve upper limb function in stroke rehabilitation.


Eligibility criteria:
inclusion criteria: * first and unilateral ischemic or hemorrhagic stroke, in the middle cerebral artery, confirmed by imaging; * age equal ou greater than 30 years old; * preserved congnitive function, corresponding to a score higher than 23 in the mini mental state examination (mmse); * ability to perform active movement in the contralesional upper limb (ul) of at least 15° in the shoulder and elbow. exclusion criteria: * body mass index (bmi) less than 18,5 and greater than 30; * hemi-spatial neglect and/or uncorrected visual changes; * musculoskeletal or neurological conditions which may affect uls and/or trunk function; * pain in the uls; * severe sensorimotor impairment, corresponding to a score less than 39 in the fugl-meyer assessment scale - upper extremity (fmas-ue); * lesions on the skin of the affected forearm; * severe spasticity (modified ashworth \>3); * severe muscle contractures on the affected forearm; * pacemaker; * osteosynthesis or metallic implants; * pregnancy; * adverse skin reaction to electrodes' gel.

Keywords: functional eletrical stimulation stroke upper limb
renasight clinical application, review and evaluation (renacare) study

Conditions: Kidney Diseases

Summary: this study is an open-label, multi-center study evaluating the clinical utility of renasight in the diagnosis and management of kidney disease.

patients who are prospectively enrolled in the study will have blood or buccal swab samples sent to the natera clinical lab for renasight testing at the time of enrollment. physicians will receive renasight test results which may be used in clinical decision-making. at enrollment and at 1 month and 1 year following enrollment, clinical data will be submitted, and physician and subject questionnaires will be completed. additional clinical follow-up and patient questionnaires may be completed at 2 and 3 years following enrollment.

Eligibility criteria:
inclusion criteria: * patients must meet all the following selection criteria to be eligible for the study. eligibility will be assessed by the investigator: 1. male or female patients, age 18 years or older at the time of signing the informed consent form (icf). if over the age of 65, patient must have a family history of ckd or clinical suspicion of genetic disorder. 2. able to read, understand, and provide written informed consent 3. willing and able to comply with the study-related procedures 4. diagnosis of kidney disease, and/or one of the following without any kidney biopsy (note: can be newly diagnosed or existing patient): 1. nephropathy associated with diabetes mellitus (dm)\* 2. nephropathy associated with hypertension\* 3. cystic nephropathy\* 4. congenital nephropathy 5. tubulointerstitial disease of unknown etiology 6. proteinuric disease suggestive of a primary glomerulopathy by clinical evaluation 7. early, severe or familial hypertension 8. thrombotic microangiopathy 9. electrolyte and acid base disorder 10. nephrolithiasis with family history 11. ckd of unknown cause after standard nephrological evaluation 12. end stage kidney disease (esrd) \*total number of patients in each of these categories will not exceed 10% of total cohort exclusion criteria: * patients are not eligible for the study if they meet any of the following criteria, as assessed by the investigator: 1. age less than 18, or greater than 65 without a family history of ckd or clinical suspicion of genetic disorder 2. history of renal transplant 3. clinical features and a kidney biopsy diagnosis strongly indicative of a secondary nephropathy (e.g., diabetic nephropathy, lupus nephritis, acute kidney injury) 4. previously confirmed diagnosis of a hereditary kidney disease via genetic testing.

Keywords: chronic kidney disease